Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
PTC Therapeutics, Inc. (NASDAQ:PTCT) traded sigificantly higher Monday after having published a positive update from its risdiplam trial in type 1 SMA babies.
The Rating
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
William Blair analyst Raju Prasad accordingly upgraded PTC to Outperform.
The Thesis
Risdiplam’s efficacy data compares favorably with that of Spinraza, and the drug also boasts superior convenience and strong tolerability.
“Risdiplam results shown at CureSMA give us increased confidence that the drug is achieving a clinical benefit and while Roche is responsible for commercialization, we believe that, if successful, risdiplam could conservatively net about $150 million in peak royalties to PTC as well as an additional $410 million in remaining milestones,” Prasad wrote in a note.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The prospects for risdiplam compound additional opportunities for Translarna’s label and geographic market expansion.
Translarna recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use to expand the patient range. PTC has projected 2018 revenue of $170 million to $185 million with 15-percent compound annual growth through 2022.
“Overall, we believe that PTC has several promising pipeline therapies, highlighted by the presentations of its programs in Huntington's disease, familial dysautonomia, spinal muscular atrophy, and oncology (PTC596 and PTC299), and we will continue to monitor these preclinical programs as they advance into the clinic,” Prasad wrote.
Price Action
At time of publication, PTC shares were trading up 26 percent at a rate of $47.32.
Related Links:
Verastem Shares Hit Highest Level Since 2015 On Duvelisib Data
Intellia Confirms Crispr Risk Irrelevant To Its Program, With No Adjustments Needed
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.